Cannabis Science Inc. Promotes Robert Kane To Chief Financial Officer (CFO), Board Of Directors

Cannabis Science Inc. Promotes Robert Kane To Chief Financial Officer (CFO), Board Of Directors

 

COLORADO SPRINGS, Colo., Nov. 20, 2013 /PRNewswire/ -- Cannabis Science, Inc. (NASDAQ OTC: CBIS), announces the appointment of Robert Kane as its new Chief Financial Officer, also joining the Company's Board of Directors. Cannabis Science President, Dr. Robert Melamede, previously held the role of interim CFO.

"Robert Kane's experience in the financial industry and in recent years specifically in the cannabis industry will continue to benefit the Company in his enhanced position. We are honored to continue to count Robert Kane as an integral part of our top-notch team. As the new CFO for Cannabis Science, Robert will be able to apply his wide range of knowledge and expertise of the financial 'seed to sale' process to help lead Cannabis Science achieve its patient-oriented goals in this expanding market," stated Dr. Dorothy Bray, Cannabis Science's Chief Executive Officer.

Mr. Kane said, "I am incredibly excited and truly privileged to be appointed to the critical roles of Director and CFO. My previous role with Cannabis Science, including being a key spokesperson for Cannabis Science, has given me a unique insight into of the Company's shareholders, competitors, patients, investors, and potential investors. This background will serve me well as CFO, and I am more than excited to ramp up my contributions to the Company as we accelerate our growth."

For more information about Mr. Kane's background, please visit the management team section of the Cannabis Science website: http://www.cannabisscience.com/index.php/our-company/leadership/executive-management

About Cannabis Science, Inc.
Cannabis Science, Inc. takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. The medicinal use of cannabis has an extensive history dating back thousands of years, and currently there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illnesses. Our initial focus is on skin and other cancers including HIV related cancers such as Kaposi's sarcoma.

Forward Looking Statements
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as "anticipate," "seek," intend," "believe," "plan," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.

Cannabis Science, Inc.
Colorado Springs, Colorado

Dr. Dorothy Bray, CEO & Director
[email protected]

For Investor Inquires:Robert Kane, CFO & Director
[email protected] +1.561.420.4824

SOURCE Cannabis Science, Inc.

Suggested Articles

Yale scientists have combined the gene-editing system CRISPR with gene therapy to help the immune system find tough-to-spot tumor cells.

The planned deal hit a wall when a special committee set up by Eidos turned down BridgeBio’s third and final offer.

Shares in ReNeuron fell more than one-third after the release of top-line data at the start of the month but the biotech argued the data are positive.